This webinar addresses the following topics pertaining to Triple Negative Breast Cancer:
- Recent changes in standard of care therapy.
- The use of chemotherapy in patients who are found to have residual breast cancer.
- Post neoadjuvant therapy and the use of immunotherapy, both in the early stage and metastatic settings.
- Some of the novel treatment strategies that are under investigation for the treatment of patients with metastatic TNBC.
Ayca Gucalp, MD, Assistant Attending, Breast Medicine Service, Memorial Sloan Kettering Cancer Center.
Dr. Gucalp is a medical oncologist with a clinical practice dedicated exclusively to the care of patients diagnosed with breast cancer. Her research activities are focused on the development of novel therapeutic strategies for the treatment of triple negative breast cancer (TNBC). She has a particular interest in evaluating the underlying biology of TNBC, with the goal of developing more effective and less toxic therapeutic strategies for the management of patients with this subtype of breast cancer.
Dr. Gucalp has conducted several prospective therapeutic trials enrolling patients with TNBC, including a pivotal study establishing the potential role of anti-androgen receptor (AR) agents in the rare TNBCs that are AR-positive.